Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes: Role of complement and inhibition by soluble CR1 and anti-C5a antibody

Circulation

Volumn 99, Issue 17, 1999, Pages 2302-2309

  Szebeni, Janos ^a   Fontana, John L ^b   Wassef, Nabila M ^a   Mongan, Paul D ^b   Morse, David S ^c   Dobbins, David E ^b   Stahl, Gregory L ^c   Bünger, Rolf ^b   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blood cells; Hemodynamics; Hypertension, pulmonary; Immune system; Thromboxane

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; HEMOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INDOMETACIN; LIPID; LIPOSOME; MONOCLONAL ANTIBODY; THROMBOXANE B2; ZYMOSAN;

ALLERGY; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARDIOPULMONARY HEMODYNAMICS; COMPLEMENT ACTIVATION; DOSE RESPONSE; FEMALE; HEART OUTPUT; HEART RATE; HYPERTENSION; IMMUNE SYSTEM; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SWINE; SYSTEMIC VASCULAR RESISTANCE;

EID: 0032954323     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.17.2302     Document Type: Article

References (32)

1. Allen TM. Liposomes: opportunities in drug delivery. Drugs. 1997; 54(suppl 4):8-14.
2. Sculier JP, Coune A, Brassinne C, Laduron C, Atassi G, Ruysschaert JM, Fruhling J. Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent: a pilot study with pharmacokinetic data. J Clin Oncol. 1986;4:789-797.
3. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berstein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med. 1991;114:664-666.
4. Ringdén O. Andström E, Remberger M, Svahn BM, Tollemar J. Allergic reactions and other rare side effects of liposomal amphotericin. Lancet. 1994;344:1156-1157.
5. Laing RBS, Milne LJR, Leen CLS, Malcolm GP, Steers AJW. Anaphylactic reactions to liposomal amphotericin. Lancet. 1994;344:682.
6. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol. 1995;13:1777-1785.
7. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia. 1996;10(suppl 2):S93-S96.
8. Dezube BJ. Safety assessment: Doxil® (doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi's sarcoma. In: Doxil Clinical Series. Califon, NJ: Gardiner-Caldwell SynerMed; 1996:1-8.
9. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997;54(suppl 4):30-35.
10. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst. 1998;15:57-89.
11. Marceau F, Lundberg C, Hugli TE. Effects of anaphylatoxins on circulation, Immunopharmacol. 1987;14:67-84.
12. Hammerschmidt DE, Hudson LD, Weaver LJ, Craddock PR, Jacob HS. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Lancet. 1980;1:947-949.
13. Moore FD. Therapeutic regulation of the complement system in acute injury states. Adv Immunol. 1994;56:267-299.
14. Wassef NM, Johnson SH, Graeher GM, Swartz GM, Schultz CL, Hailey JR, Johnson AJ, Taylor DG, Ridgway RL, Alving CR. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol. 1989;143:2990-2995.
15. Rudolph AS. Encapsulation of hemoglobin in liposomes. In: Winslow RM. Vandegriff KD, Intaglietta M, eds. Blood Substitutes. Physiological Basis of Efficacy. Boston. Mass: Birkhauser; 1995:98-104.
16. Rabinovici R, Phillips WT, Feuerstein G, Rudolph AS. Encapsulation of hemoglobin in liposomes. In: Rabinovici R, Feuerstein G, Rudolph AS, eds. Red Blood Cell Substitutes: Fundamental Principles and Clinical Applications. New York. NY: Marcel Dekker; 1998:263-287.
17. McLoughlin TM, Fontana JL, Alving B, Mongan PD, Bünger R. Profound normovolemic hemodilution: hemostatic effects in patients and in a porcine model. Anesth Analg. 1996;83:459-465.
18. Szebeni J, Wassef NM, Hartman KR, Rudolph AS, Alving CR. Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin. Transfusion. 1997;37:150-159.
19. Szebeni J, Wassef NM, Spielberg H, Rudolph AS, Alving CR. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin. Biochem Biophys Res Commun. 1994;205:255-263.
20. Stahl GL, Behroozi F, Morrissey M. Monoclonal antibody, GS1, functionally inhibits porcine C5a induced neutrophil activation, but not C5b-9 formation. FASEB J. 1997;11:A331. Abstract.
21. Tofukuji M, Stahl GL, Agah A, Metais C, Simons M, Sellke FW. Anti-C5a monoclonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dsyfunction. J Thorac Cardiovasc Surg. 1998;116:1060-1068.
22. Weisman HF, Bartow T, Leppo MK, Marsh HCJ, Carson GR. Concino MF. Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249: 146-151.
23. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis following myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259-2267.
24. Rang, YH, Mallet RT, Bünger R. Coronary autoregulation and purine release in normoxic heart at various cytoplasmic phosphorylation potentials: disparate effects of adenosine. Pflugers Arch. 1992;421:188-199.
25. Szebeni J, Wassef NM, Rudolph AS, Alving CR. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim Biophys Acta. 1996;1285: 127-130.
26. Stahl G, Morse DS, Martin SL. Eicosanoid production from porcine neutrophils and platelets: differential production with various agonists. Am J Physiol. 1997;272:C1821-C1828.
27. Hansch GM, Seitz M, Martinotti G, Betz M, Rauterberg EW, Gemsa D. Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement components. J Immunol. 1984;133:2145-2151.
28. Martin SE, Chenoweth DE, Engler RL, Roth DM, Longhurst JC. C5a decreases regional coronary blood flow and myocardial function in pigs: implications for a granulocyte mechanism. Circ Res. 1988;63:483-491.
29. Fletcher MP, Stahl GL, Longhurst JC. C5a-induced myocardial ischemia: role for CD18-dependent PMN localization and PMN-platelet interactions. Am J Physiol. 1993;265:H1750-H1761.
30. Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268: H448-H457.
31. Stahl GL, Amsterdam EA, Symons JD, Longhurst JC. Role of thromboxane A2 in cardiovascular response to intracoronary C5a. Circ Res. 1990;66:1103-1111.
32. Szebeni J, Muggia FM, Alving CR. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst. 1998;90:300-306.